Adjuvant Nivolumab IV to SC Switch in Melanoma and Urothelial Carcinoma

Phase 2, open-label, single-arm trial of nivolumab in melanoma and urothelial carcinoma (UC), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of Participants That Prefer Nivolumab SC at the First Assessment of Patient Preference Using Patient Experience and Preference Questionnaire (PEPQ) (Question 1). Planned start May 2023; status: withdrawn.